Evotec (EVO) slashes 2026 outlook as losses widen and revenue drops 19%
Rhea-AI Filing Summary
Evotec SE reports a weak first half of 2026, with Group revenue down 19.2% to €300.1 m from €371.2 m, reflecting softer customer demand, weaker sales-to-revenue conversion and the non-repeat of a large Sandoz license deal. At constant exchange rates, revenue was €313.2 m. Gross margin turned to (1.0)% from 13.6%, as underutilisation in Discovery & Preclinical Development (D&PD) and negative mix effects in Just – Evotec Biologics (JEB) weighed on profitability.
Other operating expenses surged to €51.2 m, including a €42.3 m impairment on a Hamburg lab building, and reorganization costs linked to Project Horizon reached €98.9 m. Adjusted Group EBITDA declined to a loss of €42.7 m versus a €1.9 m loss a year earlier, and net loss widened to €168.6 m from €75.1 m. Operating cash flow was negative €111.1 m. These effects were partly offset by a €71.9 m gain from the sale of Tubulis GmbH and tight control of R&D and SG&A spending.
Total liquidity stood at €465.6 m, supported by €116.1 m of new senior unsecured convertible bonds to finance Horizon. The equity ratio fell to 42.3%. Updated 2026 guidance now targets revenue of €570–610 m and adjusted EBITDA of €(70) to €(105) m, materially below previous ranges, mainly due to lower-than-expected strategic partnership and milestone contributions, with some revenues shifting into 2027.
Positive
- Total liquidity of €465.6 m at 30 June 2026, underpinned by strong cash and investments, provides financial flexibility despite higher losses.
- Sale of Tubulis GmbH generated €89.3 m cash and a €71.9 m gain, strengthening liquidity and non-operating earnings.
- Project Horizon targets €75 m annual run-rate cost savings by end-2027, with 20–30% of savings expected in 2026 and early measures already implemented.
- Operating costs are being reduced: R&D expenses fell 30.8% to €20.3 m and SG&A decreased 11.1% to €83.1 m versus H1 2025.
Negative
- Group revenue declined 19.2% to €300.1 m in H1 2026, driven by weaker demand and the non-repeat of prior-year license income.
- Profitability deteriorated sharply, with gross margin turning to (1.0)% from 13.6% and adjusted EBITDA loss widening to €42.7 m from €1.9 m.
- Reported results include heavy one-offs: €98.9 m in reorganization costs and a €42.3 m impairment on a Hamburg laboratory building.
- Net loss more than doubled to €168.6 m, while operating cash flow swung to an outflow of €111.1 m versus €5.3 m used in H1 2025.
- The company cut its 2026 outlook to revenue of €570–610 m and adjusted EBITDA of €(70) to €(105) m, from previously €700–780 m and €0–40 m.
- Segment performance weakened: D&PD revenue fell 15.2% to €228.1 m and JEB revenue fell 29.3% to €72.3 m, both now loss-making on an adjusted EBITDA basis.
Filing Explained
The disclosed holder-ownership exposure is conditional conversion into new shares, not a completed equity issuance.
Evotec filed a Form 6-K on
That structure creates a conditional ownership exposure for existing common holders: conversion into new shares could increase the total share count and reduce existing holders’ percentage ownership, while conversion into existing shares would not itself add shares.
The interim statements say they were prepared on a going-concern basis and that there are no material uncertainties casting significant doubt on that assumption. The strategic evaluation announced with the first-quarter results remains ongoing alongside the Horizon transformation, so its outcome is unresolved in this filing.
Governance also changed during the period: Camilla Macapili Languille left the Supervisory Board effective
Key Figures
Key Terms
Adjusted EBITDA financial
Project Horizon financial
senior unsecured convertible bonds financial
fair value hierarchy financial
Level 3 financial
equity ratio financial
Earnings Snapshot
For full-year 2026, Evotec expects Group revenue of approximately €570–610 m (€595–635 m CER) and adjusted Group EBITDA of approximately €(70) to €(105) m (€(60) to €(90) m CER), reduced from previous guidance of €700–780 m revenue and €0–40 m adjusted EBITDA.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How did Evotec (EVO) perform financially in the first half of 2026?
What is Evotec’s updated full-year 2026 guidance?
How strong is Evotec’s liquidity and balance sheet as of June 30, 2026?
What were the main one-off charges impacting Evotec’s H1 2026 results?
How did Evotec’s business segments D&PD and JEB perform in H1 2026?
What is Project Horizon and its expected financial impact on Evotec (EVO)?
What were the cash flow trends for Evotec in the first half of 2026?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August, 2026
COMMISSION FILE NUMBER 001-34041
Evotec SE
(Translation of registrant’s name into English)
Essener Bogen 7
22419 Hamburg
Germany
Tel: +49 40 560810
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
On August 13, 2026, Evotec SE (the “Company”) issued its Half-Year Interim Report 2026. A copy of the Half-Year Interim Report 2026 is furnished as Exhibit 99.1 to this Report on Form 6-K. The related Corporate News is attached as Exhibit 99.2 hereto.
EXHIBIT INDEX
| Exhibit | Description of Exhibit | |
| 99.1 | Half-Year Interim Report 2026 | |
| 99.2 | Evotec Announces Second Quarter and First Half 2026 Results: Growing Commercial Momentum |
SIGNATURE
Pursuant to the requirements, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Evotec SE | ||
| By: | /s/ Claire Hinshelwood | |
| Name: Claire Hinshelwood | ||
| Title: Chief Financial Officer | ||
Date: August 13, 2026
Exhibit 99.1
For further information, please contact: Dr. Sarah Fakih, EVP Head of Global Communications and Investor Relations, sarah.fakih@evotec.com, M. +49.(0)151 70 688 784, www.evotec.com
 | INTERIM STATEMENT 6M 2026 |
HIGHLIGHTS
| 4 | D&PD NET SALES1 EXCLUDING STRATEGIC PARTNERSHIPS INCREASED BY 28% YOY, REFLECTING STRONG CUSTOMER ENGAGEMENT AND COMMERCIAL EXECUTION |
| 4 | JUST – EVOTEC BIOLOGICS (“JEB”) SHOWED CONTINUED PROGRESS WITH HIGH CAPACITY UTILIZATION AND EXPANDED CUSTOMER BASE |
| 4 | HORIZON TRANSFORMATION ON TRACK: OPERATIONAL AND COST INITIATIVES PROGRESSING AS PLANNED |
| 4 | JEB LAUNCHED J.TRAIN TURNKEY CONTINUOUS MANUFACTURING; EVOTEC ADVANCED AN ALMIRALL DERMATOLOGY DRUG CANDIDATE PRE-CLINICALLY |
| 4 | FY 2026 OUTLOOK UPDATED, REFLECTING PARTNERSHIP TIMING SHIFTS AND LOWER REVENUE CONVERSION |
H1 RESULTS IMPACTED BY CHALLENGING MARKET CONDITIONS AND REVENUE TIMING EFFECTS DESPITE POSITIVE COMMERCIAL EXECUTION
| 4 | Group revenues decreased by 19.2% to € 300.1 m (6M 2025: € 371.2 m) |
| 4 | Total D&PD revenue decreased by 15.2% to € 228.1 m (6M 2025: € 269.0 m), primarily driven by weak sales to revenue conversion across all business areas; |
| Just – Evotec Biologics revenue decreased by 29.3% to € 72.3 m (6M 2025: € 102.2 m) primarily driven by the Sandoz License sale in Q1 2025 |
| 4 | Adjusted Group EBITDA totaled € (42.7) m (6M 2025: € (1.9) m) primarily driven by lower revenues, partly offset by reduced cost of revenue as well as lower R&D and SG&A expenses |
1 Net sales are defined as signed work orders, positive change orders and negative change orders.
2
| INTERIM STATEMENT 6M 2026 |
BUSINESS DEVELOPMENT ACTIVITIES SHOW CONTINUED PROGRESS ACROSS STRATEGIC PARTNERSHIPS, PIPELINE ADVANCEMENT, BIOLOGICS INNOVATION AND GLOBAL HEALTH PROGRAMS
| 4 | June 30: Just – Evotec Biologics launches J.TRAIN, a new offering enabling biopharmaceutical companies to deploy Evotec’s proprietary continuous manufacturing technology directly within their own facilities on a turnkey basis |
| 4 | May 4: Evotec announces nomination of first small molecule preclinical development candidate from its multi-target drug discovery alliance in medical dermatology with Almirall |
| 4 | April 30: Evotec awarded two grants totaling $ 9.9 m by the Gates Foundation for drug discovery and translation in tuberculosis |
| 4 | March 23: Just – Evotec Biologics enters project agreement with BARDA to optimize biomanufacturing of antibodies against Ebola and related viruses |
| 4 | March 19: Evotec receives $10 m milestone from Bristol Myers Squibb protein degradation collaboration for phase 1 clinical study initiation |
| 4 | January 8: Just – Evotec Biologics awarded ~$ 1.7 m grant by the Gates Foundation for AI-driven optimization of monoclonal antibody developability to support affordable access |
EVENTS AFTER PERIOD-END
| 4 | Financial updates: |
| • | July 13: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook |
| • | August 6: Evotec and Odyssey Therapeutics entered an AI-enabled R&D collaboration in autoimmune and inflammatory diseases |
CORPORATE
| 4 | Leadership and governance updates: |
| • | June 11: Results of Annual General Meeting 2026: all agenda items adopted; successful new elections to the Supervisory Board |
| • | June 2: Rui Wang appointed Executive Vice President, Head of Global In Silico and AI |
| • | April 29: Dr. Wolfgang Hofmann nominated for election as independent Supervisory Board member |
| • | April 24: Claire Hinshelwood appointed successor to Paul Hitchin as Chief Financial Officer effective May 1, 2026 |
| • | April 15: Dr. Ingrid Müller appointed as Chief Operating Officer effective May 1, 2026 |
| • | April 7: Dieter Weinand nominated as Supervisory Board Chairman |
| • | April 1: Dr. Ashiq H. Khan appointed EVP Global Head, Chief Commercial Officer |
3
| INTERIM STATEMENT 6M 2026 |
| 4 | Financial and portfolio developments: |
| • | May 12: Evotec successfully placed € 116.1 m convertible bonds |
| • | April 7: Evotec received approx. $ 100 m from equity stake as part of Tubulis acquisition by Gilead Sciences. The company is eligible to receive up to approximately $ 58 m in additional contingent consideration in line with its equity participation and subject to the achievement of specified milestones |
| 4 | Strategic transformation: |
| • | March 10: Evotec announced "Horizon", the next phase of its strategic transformation designed to accelerate growth, increase agility and enhance value creation. |
| ▪ | New operating model focused on operations, science and commercial execution |
| ▪ | Structural measures expected to generate ~ € 75 m run-rate savings by end of 2027 |
| 4 | After period end: |
| • | Effective August 7, Camilla Macapili Languille has decided to step down from Evotec's Supervisory Board. The Supervisory Board has initiated the process to identify a successor. |
ADJUSTED GUIDANCE FOR FULL-YEAR 2026 CONFIRMED
| 4 | Group revenues expected in the range of € 570 – 610 m (€ 595 - 635 m CER; 2025: € 788.4 m) |
| 4 | Adjusted Group EBITDA is expected to reach € (70) – (105) m (€ (60) - (90) m CER; 2025: € 41.1 m) |
GENERAL MARKET AND HEALTHCARE ENVIRONMENT
Trends in the pharmaceutical and biotechnology sector
The biopharmaceutical industry continues to operate in a selective and evolving market environment in 2026. Although early-stage drug discovery funding remains constrained, signs of stabilization are emerging, reflected in increased financing, partnering and M&A activity across the sector. However, customers continue to act cautiously amid ongoing economic, regulatory and geopolitical uncertainties, and any broader recovery in demand is expected to occur gradually. For further information, please see the “Macroeconomic conditions and business environment” section of the 2025 Annual Report.
4
| INTERIM STATEMENT 6M 2026 |
FINANCIAL HIGHLIGHTS
Consolidated income statement & segment information
Evotec Group
| 6M 2026 | ||||||||||||||||
| in k€ | D&PD | JEB | Intersegment eliminations | Evotec Group | ||||||||||||
| Revenue1 | 227,868 | 72,254 | — | 300,123 | ||||||||||||
| Intersegment revenue | 206 | — | (206 | ) | — | |||||||||||
| Cost of revenue | (217,966 | ) | (85,510 | ) | 206 | (303,271 | ) | |||||||||
| Gross profit (loss) | 10,108 | (13,256 | ) | — | (3,148 | ) | ||||||||||
| Gross margin % | 4.4 | % | (18.3 | )% | — | % | (1.0 | )% | ||||||||
| Research and development costs | (20,337 | ) | — | — | (20,338 | ) | ||||||||||
| Selling, general and administrative expenses | (66,496 | ) | (16,582 | ) | — | (83,078 | ) | |||||||||
| Other operating income | 20,967 | 1,063 | — | 22,029 | ||||||||||||
| Other operating expenses | (49,664 | ) | (1,546 | ) | — | (51,210 | ) | |||||||||
| Reorganization costs | (98,924 | ) | — | — | (98,924 | ) | ||||||||||
| Operating income (loss) | (204,348 | ) | (30,322 | ) | — | (234,669 | ) | |||||||||
| Adjusted EBITDA | (24,438 | ) | (18,245 | ) | — | (42,684 | ) | |||||||||
| 6M 2025 | ||||||||||||||||
| in k€ | D&PD | JEB | Intersegment eliminations | Evotec Group | ||||||||||||
| Revenue | 268,969 | 102,244 | — | 371,213 | ||||||||||||
| Intersegment revenue | 29 | 23 | (52 | ) | — | |||||||||||
| Cost of revenue2 | (227,967 | ) | (92,937 | ) | 52 | (320,852 | ) | |||||||||
| Gross profit (loss) | 41,031 | 9,330 | — | 50,361 | ||||||||||||
| Gross margin % | 15.3 | % | 9.1 | % | — | % | 13.6 | % | ||||||||
| Research and development costs2 | (29,346 | ) | (62 | ) | — | (29,408 | ) | |||||||||
| Selling, general and administrative expenses2 | (77,779 | ) | (15,631 | ) | — | (93,410 | ) | |||||||||
| Other operating income | 27,885 | 1,756 | — | 29,642 | ||||||||||||
| Other operating expenses | (5,066 | ) | (535 | ) | — | (5,601 | ) | |||||||||
| Reorganization costs | 634 | — | — | 634 | ||||||||||||
| Operating income (loss) | (42,641 | ) | (5,141 | ) | — | (47,782 | ) | |||||||||
| Adjusted EBITDA | (9,329 | ) | 7,478 | — | (1,850 | ) | ||||||||||
1 Group revenue would have amounted to € 313.2 m at constant exchange rates
2 For the six months ended June 30, 2025, costs of € 14.5 m previously presented as Cost of revenue have been reclassified to Research and development costs and Selling, general and administrative expenses in the amount of € 10.4 m and € 4.1 m, respectively. For further details see
Note 2 “Basis of Preparation”. These reclassifications solely impact the D&PD segment.
5
| INTERIM STATEMENT 6M 2026 |
REPORT ON THE FINANCIAL SITUATION AND RESULTS
1. Results of operations
During the six months ended June 30, 2026, Group revenue decreased by 19.2% to € 300.1 m compared with € 371.2 m in the corresponding period of the prior year. At constant exchange rates, Group revenue declined by 15.6% to 313.2 m compared with € 371.2 m in the prior-year period. Base revenues decreased by 17.8% from € 347.5 m in 6M 2025 to € 285.8 m in 6M 2026.
Revenue in the Discovery & Preclinical Development (D&PD) segment (including intersegment revenue) declined by 15.2% to € 228.1 m in 6M 2026, compared with € 269.0 m in the prior-year period. The decrease was primarily driven by weak sales conversion across all business areas and softer-than-expected customer demand, reflecting the continued challenging market environment.
Revenue from Just – Evotec Biologics (JEB) decreased by 29.3% to € 72.3 m in 6M 2026, down from € 102.2 m in the prior-year period. The decline was primarily driven by the Sandoz License sale in Q1 2025. Excluding Sandoz License sale and negative FX-impact, revenues decreased by 2.3%.
Cost of revenue for the six months ended June 30, 2026 amounted to € 303.3 m compared with € 320.9 m in the corresponding period of 2025, resulting in a gross margin of (1.0)% (6M 2025: 13.6%). The decrease in cost of revenue was primarily driven by lower personnel and material costs in the D&PD segment.
Within D&PD, cost of revenue totaled € 218.0 m for the six months ended June 30, 2026, compared with € 228.0 m in the prior-year period. Gross margin decreased to 4.4% from 15.3% in 6M 2025, primarily driven by a lower top-line performance. D&PD saw continued underutilization which is being addressed as part of Project Horizon. Within JEB, cost of revenue decreased to € 85.5 m in the first six months of 2026, compared to € 92.9 m in the corresponding period of 2025. Gross margin declined to (18.3)% compared with 9.1% in the first six months of 2025, reflecting delayed program activities, temporarily higher material and project costs due to production phasing as well as the Sandoz License sale in Q1 2025.
R&D expenses decreased to € 20.3 m, compared to € 29.4 m in the six months ended June 30, 2025 (30.8%), driven by more focused capital allocation to selected R&D projects. Research and development expenses were incurred predominantly within the D&PD segment.
SG&A expenses for the six months ended June 30, 2026 amounted to € 83.1 m, representing a decrease of € 10.3 m or 11.1%, compared with € 93.4 m in the first six months of 2025. This change was primarily attributable to lower SG&A expenses within the D&PD segment, which declined to € 66.5 m from € 77.8 m in the first six months of 2025, mainly driven by lower IT business consultancy expenses.
For the six months ended June 30, 2026, other operating income amounted to € 22.0 m, compared with € 29.6 m in the corresponding prior-year period. The year-on-year decrease was primarily driven by the D&PD segment, where other operating income declined to € 21.0 m (6M 2025: € 27.9 m), mainly reflecting a € 7.5 m one-off insurance reimbursement related to the cyber-attack received in 2025, which did not recur in 2026.
6
| INTERIM STATEMENT 6M 2026 |
Other operating expenses increased from € 5.6 m in the first six months 2025 to € 51.2 m in the first six months 2026. The increase was primarily attributable to an impairment loss of € 42.3 m in the D&PD segment relating to a laboratory building in Hamburg, recognized during 2026.
For the six months ended June 30, 2026 Reorganization costs amounted to € 98.9 m, reflecting expenses for provisions and asset impairments related to the recently announced Project Horizon.
Adjusted Group EBITDA for the six months ended June 30, 2026 represented a loss of € 42.7 m (6M 2025: loss of € 1.9 m) mainly caused by lower revenue, partially offset by lower cost of revenue as well as reduced R&D and SG&A expenses. The adjusted EBITDA of the D&PD segment was a loss of € 24.4 m (6M 2025: loss of € 9.3 m), primarily caused by the reduced top-line performance. The adjusted EBITDA within JEB has decreased to a loss of €18.2 m (6M 2025: income of € 7.5 m), primarily driven by the non-recurring Sandoz License sale in Q1 2025.
The net loss as of June 30, 2026 totaled € 168.6 m (6M 2025: loss of € 75.1 m). The year-on-year increase in net loss was mainly driven by reorganization costs incurred in connection with the Horizon project, asset impairments and lower revenues during the period. These adverse effects were partially offset by higher non-operating income, including realized gains on investments, notably from the recent sale of Tubulis GmbH.
2. Cash flows and financial position
Net cash provided by (used in) operating activities in the first six months ended June 30, 2026 was € (111.1) m compared with € (5.3) m in the first six months 2025. This year’s figure was largely driven by lower operating performance.
Net cash provided by (used in) investing activities for the six months ended June 30, 2026 amounted to € 7.1 m (6M 2025: € (43.6) m). The increase was primarily attributable to the proceeds of € 89.3 m from the disposal of Tubulis GmbH. Conversely, the net cashflow from current investments (net) amounted to € (59.1) m (6M 2025: € 9.6 m) and originated from the net purchase of coupon bonds and money market funds. Capital expenditure decreased to € (13.3) m (6M 2025: € (37.6) m), primarily reflecting reduced investment after the sale of JUST EU at the end of 2025.
Net cash provided by (used in) financing activities was € 33.8 m in the six months ended June 30, 2026 (6M 2025: € 20.7 m) which mainly resulted from proceeds from convertible bonds and other loans of € 112.9 m (6M 2025: € 43.5 m), partially offset by repayments of loans and lease liabilities amounting to € 76.3 m. In comparison, the six months ended June 30, 2025 were negatively affected by loan repayments of € 19.3 m.
Total Liquidity decreased to € 465.6 m (31 December 2025: € 476.4 m).
3. Assets, liabilities, and stockholders’ equity
Assets
Between December 31, 2025 and June 30, 2026, total assets decreased by € 140.0 m to € 1,574.0 m (31 December 2025: € 1,713.9 m).
Investments increased by € 59.4 m to € 117.2 m (31 December 2025: € 57.9 m ). The increase was mainly due to the purchase of money market funds and short-term deposits.
Trade and other receivables decreased by € 39.6 m to € 96.4 m (December 31, 2025: € 136.0 m). The decrease was mainly due to cash receipts related to the License Agreement signed in December 2025 as part of the Sandoz transaction.
Property, plant and equipment decreased by € 104.9 m to € 449.8 m (December 31, 2025: € 554.6 m). The decrease was mainly due to impairment and depreciation of € 81.5 m and € 44.6 m, respectively, that exceeded capital expenditures of € 14.2 m and a positive foreign exchange effect totaling € 6.1 m.
7
| INTERIM STATEMENT 6M 2026 |
Liabilities
Between December 31, 2025 and June 30, 2026, total liabilities increased by € 8.2 m to € 908.4 m (31 December 2025: € 900.2 m).
Current and Non-current financial liabilities increased by € 27.1 m to € 475.9 m (31 December 2025: € 448.7 m). The increase was mainly due to € 104.5 m of issuance of convertible bonds, partially offset by € 76.3 m of repayments of loans and lease liabilities.
Trade and other payables decreased by € 15.6 m to € 49.1 m (31 December 2025: € 64.8 m). The decrease occurred in the normal course of business.
Current and Non-current contract liabilities decreased by € 45.1 m to € 205.1 m (December 31, 2025: € 250.2 m). The decrease occurred as a result of greater revenue earned versus upfront payments received.
Current and Non-current provisions increased by € 42.4 m to € 119.0 m (December 31, 2025: € 76.6 m), mainly due to Horizon, including € 48.6 m attributable to personnel measures (including severance payments) and € 10.6 m attributable to the recognition of restoration obligations for impacted leases. The provision increase due to Horizon was partially offset by € 16.6 m in reductions in short-term incentive accruals.
Stockholders’ equity
Total stockholders’ equity decreased by € 148.1 m to € 665.6 m (December 31, 2025: € 813.7 m) predominantly as a result of the net loss of the six months ended June 30, 2026 of € 168.6 m, a positive change in other comprehensive income of € 9.3 m driven by foreign currency translation adjustments and a positive change in additional paid-in capital of € 10.4 m driven by the recognition of € 8.4 m related to the issuance of convertible bonds.
Evotec’s equity ratio as of June 30, 2026 decreased to 42.3% (December 31, 2025: 47.5%).
4. Human Resources
Employees
Headquartered in Hamburg, Germany, the Evotec Group employed an average of 4,461 people globally as of June 30, 2026, which corresponds to a decrease of 6.2% to the prior year’s end. Overall, the number of employees decreased by 296 compared to the twelve months average ended December 31, 2025 with 4,757 . The decrease primarily reflects the divestiture of Just –Evotec Biologics EU, completed in December 2025, as well as workforce reductions associated with Project Horizon during H1 2026. Other workforce movements also contributed to the overall decrease in employee headcount.
RISKS AND OPPORTUNITIES MANAGEMENT
The risks and opportunities described in Evotec’s ‘Risk and Opportunities Report’ of the 2025 Annual Report remain mainly unchanged.
8
| INTERIM STATEMENT 6M 2026 |
UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Income statement of the Evotec Group for the period January 1 to June 30
| in k€ except share and per share data | 6M 2026 | 6M 2025 | ||||||
| Revenue | 300,123 | 371,213 | ||||||
| Cost of revenue1 | (303,271 | ) | (320,852 | ) | ||||
| Gross profit (loss) | (3,148 | ) | 50,361 | |||||
| Operating income (expenses) | ||||||||
| Research and development costs1 | (20,338 | ) | (29,408 | ) | ||||
| Selling, general and administrative expenses1 | (83,078 | ) | (93,410 | ) | ||||
| Other operating income | 22,029 | 29,642 | ||||||
| Other operating expenses | (51,210 | ) | (5,601 | ) | ||||
| Reorganization costs | (98,924 | ) | 634 | |||||
| Total operating income (expenses) | (231,521 | ) | (98,143 | ) | ||||
| Operating income (loss) | (234,669 | ) | (47,782 | ) | ||||
| Non-operating income (expenses) | ||||||||
| Realized gain (loss) on investments and financial instruments revaluation | 70,027 | 427 | ||||||
| Share of profit (loss) and revaluation of at-equity investments | (1,155 | ) | (1,217 | ) | ||||
| Other financial income | 1,976 | 2,422 | ||||||
| Other financial expenses | (5,557 | ) | (8,402 | ) | ||||
| Other non-operating income (expenses) | (922 | ) | (18,719 | ) | ||||
| Net income (loss) before taxes | (170,300 | ) | (73,270 | ) | ||||
| Income taxes | 1,715 | (1,785 | ) | |||||
| Net income (loss) | (168,585 | ) | (75,055 | ) | ||||
| Weighted average shares outstanding | 177,618,086 | 177,561,699 | ||||||
| Net result per share (basic) | (0.95 | ) | (0.42 | ) | ||||
| Net result per share (diluted) | (0.95 | ) | (0.42 | ) | ||||
1 For the six months ended June 30, 2025, costs of € 14,541k previously presented as Cost of revenue have been reclassified to Research and development costs and Selling, general and administrative expenses in the amount of € 10,439k and € 4,102k, respectively. For further details see Note 2 “Basis of Preparation”.
9
| INTERIM STATEMENT 6M 2026 |
Statement of Comprehensive Income of the Evotec Group for the period January 1 to June 30
| in k€ | 6M 2026 | 6M 2025 | ||||||
| Net income (loss) | (168,585 | ) | (75,055 | ) | ||||
| Items which are not re-classified to the income statement | ||||||||
| Revaluation of equity investments | (724 | ) | (846 | ) | ||||
| Items which have to be re-classified to the income statement at a later date | ||||||||
| Foreign currency translation | 9,722 | (35,397 | ) | |||||
| Revaluation and disposal of other current investments | 336 | 1,108 | ||||||
| Other comprehensive income (loss) | 9,334 | (35,135 | ) | |||||
| Total comprehensive income (loss) | (159,251 | ) | (110,190 | ) | ||||
10
| INTERIM STATEMENT 6M 2026 |
Statement of Cash Flows of the Evotec Group for the period from January 1 to June 30
| in k€ | 6M 2026 | 6M 2025 | ||||||
| Cash flows from operating activities: | ||||||||
| Net income (loss) | (168,585 | ) | (75,055 | ) | ||||
| Adjustments to reconcile net income to net cash used in operating activities1 | 69,409 | 40,684 | ||||||
| Change in assets and liabilities | (11,926 | ) | 29,120 | |||||
| Net cash provided by (used in) operating activities | (111,102 | ) | (5,252 | ) | ||||
| Cash flow from investing activities: | ||||||||
| Interest received | 4,146 | 2,463 | ||||||
| Purchase of property, plant and equipment | (13,280 | ) | (37,637 | ) | ||||
| Proceeds from sale of property, plant and equipment | 92 | 25 | ||||||
| Purchase of intangible assets and additions to capitalized development expenditures | (8,522 | ) | (8,061 | ) | ||||
| Investments to acquire associated companies, other non-current investments and convertibles | (2,635 | ) | (9,657 | ) | ||||
| Proceeds from the disposal of associated companies, other non-current investments and convertibles, net of transaction costs | 90,557 | (274 | ) | |||||
| Purchase of current investments | (70,000 | ) | — | |||||
| Proceeds from sale of current investments | 10,865 | 9,590 | ||||||
| Proceeds from (payments due to) the disposal of subsidiaries | (4,140 | ) | — | |||||
| Net cash provided by (used in) investing activities | 7,082 | (43,550 | ) | |||||
| Cash flow from financing activities: | ||||||||
| Interest paid | (3,015 | ) | (3,695 | ) | ||||
| Proceeds from convertible bonds and other loans² | 112,931 | 43,513 | ||||||
| Proceeds from the exercise of share options | 131 | 213 | ||||||
| Repayment of loans | (65,791 | ) | (6,689 | ) | ||||
| Repayment of lease liabilities | (10,482 | ) | (12,610 | ) | ||||
| Net cash provided by (used in) financing activities | 33,774 | 20,733 | ||||||
| Net increase (decrease) in Cash and cash equivalents | (70,247 | ) | (28,070 | ) | ||||
| Effects of revaluation and of movements in exchange rates on cash held | 86 | (10,492 | ) | |||||
| Cash and cash equivalents at beginning of year | 418,517 | 306,387 | ||||||
| Cash and cash equivalents at end of the period | 348,356 | 267,825 | ||||||
1 Adjustments include the following material non recurring items: Impairments in the amount of €81,482 k partially offset by the gain from the sale of Tubulis GmbH in the amount of €(71,929) k.
2 Including transactions costs, which were presented as a separate line item in the amount of €(448) k in the published Half Year Interim Report 2025.
11
| INTERIM STATEMENT 6M 2026 |
Statement of financial position of the Evotec Group as of June 30, 2026 and as of December 31, 2025
| in k€ | 06/30/2026 | 12/31/2025 | ||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | 348,356 | 418,517 | ||||||
| Investments | 117,231 | 57,873 | ||||||
| Trade and other receivables | 96,353 | 135,963 | ||||||
| Contract assets | 33,286 | 28,295 | ||||||
| Inventories | 38,563 | 29,317 | ||||||
| Current tax assets | 36,819 | 38,453 | ||||||
| Other current financial assets including derivatives | 18,032 | 20,217 | ||||||
| Prepaid expenses and other current assets | 40,246 | 30,480 | ||||||
| Assets classified as held for sale | — | 3,830 | ||||||
| Total current assets | 728,888 | 762,945 | ||||||
| Non-current assets: | ||||||||
| Non-current investments and other non-current financial assets | 39,070 | 48,004 | ||||||
| Investments in associates and joint ventures | 3,477 | 4,629 | ||||||
| Property, plant and equipment | 449,773 | 554,626 | ||||||
| Intangible assets and goodwill | 306,511 | 303,936 | ||||||
| Deferred tax assets | 1,890 | 2,949 | ||||||
| Non-current tax assets | 43,269 | 36,349 | ||||||
| Other non-current assets | 1,097 | 507 | ||||||
| Total non-current assets | 845,087 | 951,000 | ||||||
| Total assets | 1,573,975 | 1,713,945 | ||||||
12
| INTERIM STATEMENT 6M 2026 |
| in k€ | 06/30/2026 | 12/31/2025 | ||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Current financial liabilities | 61,544 | 104,720 | ||||||
| Trade and other payables | 49,128 | 64,763 | ||||||
| Contract liabilities | 68,414 | 104,849 | ||||||
| Deferred income | 4,111 | 3,220 | ||||||
| Provisions | 92,763 | 58,543 | ||||||
| Current income tax liabilities | 8,897 | 10,578 | ||||||
| Other current liabilities | 27,602 | 21,401 | ||||||
| Total current liabilities | 312,460 | 368,074 | ||||||
| Non-current liabilities: | ||||||||
| Non-current financial liabilities | 414,322 | 344,008 | ||||||
| Deferred tax liabilities | 10,269 | 14,735 | ||||||
| Provisions | 26,229 | 18,035 | ||||||
| Contract liabilities | 136,707 | 145,324 | ||||||
| Deferred income | 7,073 | 8,350 | ||||||
| Other non-current liabilities | 1,337 | 1,715 | ||||||
| Total non-current liabilities | 595,937 | 532,167 | ||||||
| Stockholders’ equity: | ||||||||
| Share capital | 177,910 | 177,779 | ||||||
| Treasury shares, at cost | (980 | ) | (1,548 | ) | ||||
| Additional paid in capital | 1,468,893 | 1,458,466 | ||||||
| Retained Earnings | (944,472 | ) | (775,887 | ) | ||||
| Accumulated other comprehensive income | (35,772 | ) | (45,106 | ) | ||||
| Total stockholders' equity | 665,578 | 813,704 | ||||||
| Total liabilities and stockholders’ equity | 1,573,975 | 1,713,945 | ||||||
13
| INTERIM STATEMENT 6M 2026 |
Statement of changes in stockholders' equity of the Evotec Group for the period January 1 to June 30
| Share capital | Income
and expense recognized in other comprehensive income | |||||||||||||||||||||||||||||||
| in k€ except share data | Shares | Amount | Treasury shares, at cost | Additional
paid in capital | Foreign currency translation | Revaluation reserve | Retained Earnings | Total stockholders' equity | ||||||||||||||||||||||||
| Balance at January 1, 2025 | 177,553,456 | 177,553 | — | 1,454,688 | 5,078 | (12,427 | ) | (672,370 | ) | 952,525 | ||||||||||||||||||||||
| Exercised stock options | 213,085 | 213 | — | — | — | — | — | 213 | ||||||||||||||||||||||||
| Stock option plan | — | — | — | 3,239 | — | — | — | 3,239 | ||||||||||||||||||||||||
| Other comprehensive income | — | — | — | — | (35,397 | ) | 262 | — | (35,135 | ) | ||||||||||||||||||||||
| Net income (loss) for the period | — | — | — | — | — | — | (75,055 | ) | (75,055 | ) | ||||||||||||||||||||||
| Total comprehensive income (loss) | — | — | — | — | (35,397 | ) | 262 | (75,055 | ) | (110,190 | ) | |||||||||||||||||||||
| Balance at June 30, 2025 | 177,766,541 | 177,766 | — | 1,457,927 | (30,319 | ) | (12,165 | ) | (747,425 | ) | 845,787 | |||||||||||||||||||||
| Balance at January 1, 2026 | 177,778,907 | 177,779 | (1,548 | ) | 1,458,466 | (33,954 | ) | (11,154 | ) | (775,887 | ) | 813,704 | ||||||||||||||||||||
| Exercised stock options | 130,652 | 131 | — | — | — | — | — | 131 | ||||||||||||||||||||||||
| Stock option plan | — | — | — | 2,582 | — | — | — | 2,582 | ||||||||||||||||||||||||
| Release of treasury shares to employees | — | — | 568 | (568 | ) | — | — | — | — | |||||||||||||||||||||||
| Issuance of convertible bonds | — | — | — | 8,412 | — | — | — | 8,412 | ||||||||||||||||||||||||
| Other comprehensive income | — | — | — | — | 9,722 | (387 | ) | — | 9,334 | |||||||||||||||||||||||
| Net income (loss) for the period | — | — | — | — | — | — | (168,585 | ) | (168,585 | ) | ||||||||||||||||||||||
| Total comprehensive income (loss) | — | — | — | — | 9,722 | (387 | ) | (168,585 | ) | (159,251 | ) | |||||||||||||||||||||
| Balance at June 30, 2026 | 177,909,559 | 177,910 | (980 | ) | 1,468,892 | (24,232 | ) | (11,541 | ) | (944,472 | ) | 665,578 | ||||||||||||||||||||
14
| INTERIM STATEMENT 6M 2026 |
NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1. Corporate information
Evotec SE, including its subsidiaries and other affiliates ("Evotec", the "Group" or the "Company") is a life science company, continuously driving innovative approaches to develop new pharmaceutical products. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships with leading pharma and biotechnology companies as well as academic institutions, patient advocacy groups and venture capital partners.
Evotec SE, located in Hamburg (Essener Bogen 7, 22419 Hamburg, Germany) is registered in the Commercial Registry of Hamburg with HRB 156381.
The Company was founded on 8 December 1993, and is listed on the Frankfurt Stock Exchange (XETRA) since 10 November 1999, Segment Prime Standard, under the ticker “EVT“ as well as on Nasdaq, New York, USA under the trading symbol “EVO“ since 8 November 2021.
2. Basis of Preparation
The interim condensed consolidated financial statements for the six months ended June 30, 2026, have been prepared in accordance with IAS 34 Interim Financial Reporting as endorsed in the European Union. The Group has prepared the interim condensed consolidated financial statements on the basis that it will continue to operate as a going concern. The Group considers that there are no material uncertainties that may cast significant doubt over this assumption. The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the Group’s consolidated financial statements and accompanying notes for the year ended December 31, 2025.
All majority-owned subsidiaries of the Company are included in the interim condensed consolidated financial statements, and intercompany transactions have been eliminated in consolidation. The interim condensed consolidated financial statements are presented in Euros. Due to rounding, amounts may not add up to totals provided.
Prior-period information
Certain prior-period amounts have been adjusted to reflect the current period presentation, following the completion of a Group reorganization that revised the functional allocation of cost centers primarily related to the In Silico & Bioinformatics and Alliance Management departments. To ensure comparability, the corresponding prior-year figures were adjusted accordingly. For the six months ended June 30, 2025, costs of € 14,541k previously presented as Cost of revenue have been reclassified to Research and development and Selling, general and administrative expenses in the amount of € 10,439k and € 4,102k, respectively.
15
| INTERIM STATEMENT 6M 2026 |
3. New Standards, Interpretations and Amendments adopted by the Group
The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those applied in the preparation of the Group’s annual consolidated financial statements for the year ended December 31, 2025, except for the adoption of the new amendments described below.
The following amendments became effective for annual periods beginning on or after January 1, 2026, and have been adopted by the Group in these interim condensed consolidated financial statements:
| • | Amendments to IFRS 9 and IFRS 7 - Classification and Measurement of Financial Instruments |
| • | Amendments to IFRS 9 and IFRS 7 - Power Purchase Agreements |
| • | Annual Improvements to IFRS Accounting Standards - Volume 11 |
The adoption of these amendments did not have a significant impact on the Group's consolidated financial statements.
Evotec has not early adopted any new standards, interpretations, or amendments that have been issued but are not yet effective. The most significant of these is IFRS 18 - Presentation and Disclosure in Financial Statements, effective for annual periods beginning on or after January 1, 2027. IFRS 18 is expected to change the presentation of the Consolidated Income Statement, differentiating between earnings from operating, investing, and financing activities, and will require structural changes to the Consolidated Cash Flow Statement, including use of operating profit (loss) as the starting point for the indirect method reconciliation. IFRS 18 will also introduce additional disclosures, including for management-defined performance measures, but will not change the recognition or measurement of transactions and balances, and therefore will not change reported net income. The Group is in the process of assessing the impact of IFRS 18 and, at this stage, is not yet able to reasonably estimate its effect on the consolidated financial statements.
Apart from IFRS 18, the Group has also assessed IFRS 19, Subsidiaries without Public Accountability: Disclosures (effective January 1, 2027), and IFRS 20, Regulatory Assets and Regulatory Liabilities (effective January 1, 2029), and concluded that neither standard is expected to be relevant to the Group's operations or to have a material impact on the Group's consolidated financial statements.
4. Significant Events during the Reporting Period
The Supervisory Board of Evotec SE appointed Claire Hinshelwood as the new Chief Financial Officer and member of the Management Board to succeed Paul Hitchin, with effect from May 1, 2026, and Ingrid Müller as the new Chief Operating Officer and member of the Management Board, with effect from May 1, 2026.
On March 10, 2026, Evotec announced ‘Horizon’, the next phase in its multi-stage transformation initiative. Horizon advances the company’s evolution by implementing a new and focused operating model built across the three pillars of operations, science, and commercial execution. For the six months ended June 2026, Evotec recorded reorganization costs totaling € 98,924k. These costs are directly attributable to the restructuring measures that are necessary for the restructuring and are not related to operating activities. Further details are provided in Note 8 Property, Plant and Equipment, and Note 11 Restructuring Provision.
16
| INTERIM STATEMENT 6M 2026 |
On May 11, 2026, Evotec SE announced its intention to issue senior unsecured convertible bonds due 2033 to finance Project Horizon, and on May 21, 2026 priced and issued the bonds in a final aggregate principal amount of € 116,100k, convertible into new and/or existing ordinary bearer shares at an initial Conversion Price of € 6.5313. The bonds have been accounted for as a compound financial instrument under IAS 32, with the liability component recognized at amortized cost and the residual equity component recognized within additional paid-in capital, together with the related allocation of transaction costs; further details are provided in Note 13 Fair Value of Financial Assets and Liabilities.
The sale of Tubulis GmbH to Gilead Sciences was completed on May 21, 2026, for a total consideration of € 93,652k. The European Investment Bank was entitled to 5.25% of the transaction proceeds. Consequently, Evotec received net cash proceeds of € 89,339k. A gain on disposal of € 71,929k was recognized within 'Realized gain (loss) on investments and financial instruments revaluation.’ Through its Evotec Ventures activities, Evotec SE held a 3.14% minority equity stake in Tubulis GmbH.
Management’s decision in June to actively market a laboratory building at the Company’s Hamburg headquarters for sublease led to the recognition of an impairment loss of €42,337k on this asset. Further details are provided in Note 8 Property, Plant and Equipment.
5. Segment information
For information on the basis used for identifying reportable segments, refer to Note 4 “Segment Information” of the 2025 Annual Report.
The segment information is as follows:
| 6M 2026 | ||||||||||||||||
| in k€ | D&PD | JEB | Intersegment eliminations | Evotec Group | ||||||||||||
| Revenue1 | 227,868 | 72,254 | – | 300,123 | ||||||||||||
| Intersegment revenue | 206 | – | (206 | ) | – | |||||||||||
| Cost of revenue | (217,966 | ) | (85,510 | ) | 206 | (303,271 | ) | |||||||||
| Gross profit (loss) | 10,108 | (13,256 | ) | – | (3,148 | ) | ||||||||||
| Research and development costs | (20,337 | ) | – | – | (20,338 | ) | ||||||||||
| Selling, general and administrative expenses | (66,496 | ) | (16,582 | ) | – | (83,078 | ) | |||||||||
| Other operating income | 20,967 | 1,063 | – | 22,029 | ||||||||||||
| Other operating expenses | (49,664 | ) | (1,546 | ) | – | (51,210 | ) | |||||||||
| Reorganization costs | (98,924 | ) | – | – | (98,924 | ) | ||||||||||
| Operating income (loss)3 | (204,348 | ) | (30,322 | ) | — | (234,669 | ) | |||||||||
| 6M 2025 | ||||||||||||||||
| in k€ | D&PD | JEB | Intersegment eliminations | Evotec Group | ||||||||||||
| Revenue1 | 268,969 | 102,244 | – | 371,213 | ||||||||||||
| Intersegment revenue | 29 | 23 | (52 | ) | – | |||||||||||
| Cost of revenue2 | (227,967 | ) | (92,937 | ) | 52 | (320,852 | ) | |||||||||
| Gross profit (loss) | 41,031 | 9,330 | – | 50,361 | ||||||||||||
| Research and development costs2 | (29,346 | ) | (62 | ) | – | (29,408 | ) | |||||||||
| Selling, general and administrative expenses2 | (77,779 | ) | (15,631 | ) | – | (93,410 | ) | |||||||||
| Other operating income | 27,885 | 1,756 | – | 29,642 | ||||||||||||
| Other operating expenses | (5,066 | ) | (535 | ) | – | (5,601 | ) | |||||||||
| Reorganization costs | 634 | – | – | 634 | ||||||||||||
| Operating income (loss)3 | (42,641 | ) | (5,141 | ) | — | (47,782 | ) | |||||||||
1Includes Revenue from contributions of € 5,440k and € 7,123k for the six months ended June 30, 2026 and 2025, respectively.
2 For the six months ended June 30, 2025, costs of € 14,541k previously presented as Cost of revenue have been reclassified to Research and development costs and Selling, general and administrative expenses in the amount of € 10,439k and € 4,102k, respectively. For further details see Note 2 “Basis of Preparation”. These reclassifications solely impact the D&PD segment.
3 Includes €33,016k (6M 2025: €33,518k) of depreciation and €3,633k (6M 2025: €4,217k) of amortization related to D&PD and includes €11,611k (6M 2025: €12,620k) of depreciation and €-k (6M 2025: €-k) of amortization related to JEB
17
| INTERIM STATEMENT 6M 2026 |
The adjusted EBITDA is derived from Operating income (loss) as follows:
| 6M 2026 | ||||||||||||
| in k€ | D&PD | JEB | Evotec Group | |||||||||
| Operating income (loss) | (204,348 | ) | (30,322 | ) | (234,669 | ) | ||||||
| Depreciation of tangible assets | 33,016 | 11,611 | 44,626 | |||||||||
| Amortization of intangible assets | 3,633 | – | 3,633 | |||||||||
| Impairment of tangible assets1 | 42,337 | – | 42,337 | |||||||||
| External cyber-related costs, net of reimbursements | – | – | – | |||||||||
| Reorganization costs | 98,924 | – | 98,924 | |||||||||
| One-off arbitration costs | – | – | – | |||||||||
| (Income) / Expenses related to the disposal of Just - Evotec Biologics EU SAS | – | 465 | 465 | |||||||||
| Other non-recurring costs | 2,000 | – | 2,000 | |||||||||
| Adjusted EBITDA | (24,438 | ) | (18,245 | ) | (42,684 | ) | ||||||
1 Impairment of tangible assets not included in reorganization costs
| 6M 2025 | ||||||||||||
| in k€ | D&PD | JEB | Evotec Group | |||||||||
| Operating income (loss) | (42,641 | ) | (5,141 | ) | (47,782 | ) | ||||||
| Depreciation of tangible assets | 33,518 | 12,620 | 46,137 | |||||||||
| Amortization of intangible assets | 4,217 | – | 4,217 | |||||||||
| Impairment of tangible assets1 | – | – | – | |||||||||
| External cyber-related costs, net of reimbursements | (6,554 | ) | – | (6,554 | ) | |||||||
| Reorganization costs | (634 | ) | – | (634 | ) | |||||||
| One-off arbitration costs | 2,765 | – | 2,765 | |||||||||
| (Income) / Expenses related to the disposal of Just - Evotec Biologics EU SAS | – | – | – | |||||||||
| Other non-recurring costs | – | – | – | |||||||||
| Adjusted EBITDA | (9,329 | ) | 7,478 | (1,850 | ) | |||||||
1 Impairment of tangible assets not included in reorganization costs
18
| INTERIM STATEMENT 6M 2026 |
6. Revenue
The following tables show the breakdown of the revenue:
| 6M 2026 | ||||||||||||
| in k€ | D&PD | JEB | Total | |||||||||
| Revenue from contracts with customers | ||||||||||||
| Fee for service and FTE-based research services | 197,842 | 66,989 | 264,830 | |||||||||
| Material re-charges to customers | 15,082 | – | 15,082 | |||||||||
| Milestone fees | 8,982 | 5,266 | 14,248 | |||||||||
| Licenses | 120 | – | 120 | |||||||||
| Other fees | 402 | – | 402 | |||||||||
| Total revenue from contracts with customers | 222,428 | 72,254 | 294,682 | |||||||||
| Timing of revenue recognition | ||||||||||||
| At a point in time | 24,586 | 5,266 | 29,852 | |||||||||
| Over a period of time | 197,842 | 66,989 | 264,830 | |||||||||
| Total revenue from contracts with customers | 222,428 | 72,254 | 294,682 | |||||||||
| Revenue by region | ||||||||||||
| USA | 138,339 | 40,618 | 178,957 | |||||||||
| Germany | 5,516 | – | 5,516 | |||||||||
| France | 9,138 | – | 9,138 | |||||||||
| United Kingdom | 28,962 | – | 28,962 | |||||||||
| Switzerland | 4,980 | 31,327 | 36,307 | |||||||||
| Rest of the world | 35,492 | 309 | 35,801 | |||||||||
| Total revenue from contracts with customers | 222,428 | 72,254 | 294,682 | |||||||||
| Revenue from contributions | 5,440 | — | 5,440 | |||||||||
| Total Revenue | 227,868 | 72,254 | 300,123 | |||||||||
19
| INTERIM STATEMENT 6M 2026 |
| 6M 2025 | ||||||||||||
| in k€ | D&PD | JEB | Total | |||||||||
| Revenue from contracts with customers | ||||||||||||
| Fee for service and FTE-based research services | 237,628 | 79,127 | 316,756 | |||||||||
| Material re-charges to customers | 16,370 | – | 16,370 | |||||||||
| Milestone fees | 500 | – | 500 | |||||||||
| Licenses | 7,178 | 23,116 | 30,294 | |||||||||
| Other fees | 170 | – | 170 | |||||||||
| Total revenue from contracts with customers | 261,847 | 102,244 | 364,090 | |||||||||
| Timing of revenue recognition | ||||||||||||
| At a point in time | 24,219 | 23,116 | 47,335 | |||||||||
| Over a period of time | 237,628 | 79,127 | 316,756 | |||||||||
| Total revenue from contracts with customers | 261,847 | 102,244 | 364,090 | |||||||||
| Revenue by region | ||||||||||||
| USA | 157,965 | 54,793 | 212,758 | |||||||||
| Germany | 12,896 | – | 12,896 | |||||||||
| France | 10,496 | 3 | 10,498 | |||||||||
| United Kingdom | 33,638 | – | 33,638 | |||||||||
| Switzerland | 5,932 | 47,448 | 53,380 | |||||||||
| Rest of the World | 40,921 | – | 40,921 | |||||||||
| Total revenue from contracts with customers | 261,847 | 102,244 | 364,090 | |||||||||
| Revenue from contributions | 7,123 | — | 7,123 | |||||||||
| Total Revenue | 268,969 | 102,244 | 371,213 | |||||||||
7. Income Taxes
The income tax amounted to a benefit of € 1,715k for the first six months until June 30, 2026 compared to an expense of € 1,785k for the six months ended June 30, 2025. This change is mainly driven by the fact that in 2026, deferred taxes were recognized on current losses in Italy and UK.
8. Property, Plant and Equipment
Property, plant and equipment amounted to € 449,773k as of June 30, 2026 (December 31, 2025: € 554,626k) and included owned property, plant and equipment as well as right-of-use assets. The decrease of € 104,853k is mainly due to impairment and depreciation (€ 81,482k and € 44,626k, respectively) that exceeded capital expenditures of € 14,176k and a positive foreign exchange effect totaling € 6,108k.
Following the announcement of Project Horizon, the Group reassessed lease terms, restoration obligations and the recoverability of right-of-use assets and leasehold improvements at affected sites. This resulted in a decrease in right-of-use assets of € 9,123k from lease remeasurements, an increase in right-of-use assets and provisions of € 8,804k relating to restoration obligations, and an impairment loss of € 41,916k which was allocated to the D&PD segment and disclosed within reorganization costs. Estimates and assumptions are regularly reviewed as the restructuring program progresses.
Following management’s decision in June 2026 to actively market a laboratory building at the Company’s Hamburg headquarters for sublease, the asset was assessed for impairment on a stand-alone basis. This assessment resulted in the recognition of an impairment loss of €42,337k, which was allocated to the D&PD segment and disclosed within other operating expenses.
The group determined the recoverable amounts of the right-of-use assets tested for impairment on a stand-alone basis based on fair value less costs of disposal. The fair value measurement was categorized within Level 3 of the fair value hierarchy and took into account real estate market conditions specific to each building.
20
| INTERIM STATEMENT 6M 2026 |
9. Intangible Assets and Goodwill
Goodwill:
Goodwill amounted to € 274,681k as of June 30, 2026, versus € 272,365k as of as of December 31, 2025. The movement during the period was due to the impact of changes in exchange rates.
The Group performs its annual impairment test over goodwill in the fourth quarter of the fiscal year and when circumstances indicate that the carrying value may be impaired. The Group’s impairment test for goodwill is based on the fair-value less costs to sell methodology.
The key assumptions used to determine the recoverable amount for the different cash generating units are disclosed in the Group’s consolidated financial statements for the year ended December 31, 2025.
Based on the analysis of the business performance as of and for the six months ended June 30, 2026 as well as on the updated guidance issued on July 13, 2026 for FY2026 and taking into account the sensitivity analysis performed, the Group has not identified any impairment trigger.
Finite lived intangible assets:
The Group also reviews its finite lived intangible assets for impairment whenever triggering events or changes in circumstances indicate that the carrying amount may not be recoverable. Following this review, the Group has not identified any impairment trigger.
10. Earnings per Share
Basic earnings per share are calculated by dividing the Net income (loss) attributable to shareholders by the weighted average number of common shares outstanding during the period, adjusted for own shares held. Diluted EPS is determined by adjusting the Net income (loss) attributable to shareholders and the weighted average number of common shares outstanding during the period, adjusted for own shares held, for the effects of all dilutive potential common shares, which comprises forward purchase contracts, restricted shares, performance shares and share options granted to employees. As Evotec reports a net loss all share equivalents are anti-dilutive, so that diluted and non-diluted (basic) earnings per share are identical (see “Net result per share (basic)” and “Net result per share (diluted)” in the Consolidated Income Statement).
21
| INTERIM STATEMENT 6M 2026 |
The weighted average number of ordinary shares is calculated as follows:
| Shares in thousands | 06/30/2026 | 12/31/2025 | ||||||
| Issued shares Jan 1 | 177,779 | 177,553 | ||||||
| Treasury shares Jan 1 | (320 | ) | (167 | ) | ||||
| Effect of weighted average stock options exercised | 159 | 192 | ||||||
| Weighted average number of shares outstanding | 177,618 | 177,578 | ||||||
The share capital of € 177,910k was divided into 177,909,559 shares. The increase in shares outstanding is related to the exercise of stock options (see Note 14).
11. Restructuring Provision
Significant portions of the restructuring provision include € 48,568k attributable to personnel measures (including severance payments) and € 10,593k attributable to restoration obligations.
The measurement of restructuring provisions is based on estimates and assumptions regarding the amount of severance payments, the timeline for the implementation of the measures and the progress of discussions in accordance with local laws and regulations. The measurement assumptions are regularly reviewed as the restructuring program progresses.
12. Financial Risk Management
The Group’s activities expose it to a variety of financial risks such as currency risks, interest rate risks, credit risks and liquidity risks. The interim condensed consolidated financial statements do not include all financial risk management information. Additional disclosures can be found in the “Risks and opportunities” described in Evotec’s Annual Report 2025.
There have not been significant changes to the risk management approach or to risk management policies since December 31, 2025.
13. Fair Value of Financial Assets and Liabilities
The Group classifies its fair value measurements using a fair value hierarchy that reflects the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety. The fair value hierarchy has the following levels:
▪ Level 1 – Quoted (unadjusted) prices in active markets for identical assets or liabilities that the Company can access at the measurement date. This includes e.g. bonds, money market funds, shares and other current cash investments.
▪ Level 2 – all significant inputs (other than quoted prices included within Level 1) are observable for the asset or liability, either directly (as prices) or indirectly (derived from prices). This includes equity investments in unlisted companies measured based on observable prices close to the balance sheet date, derivative financial instruments with a hedging relationship measured based on spot and forward rates observable in the market, as well as the liability component of issued convertible bonds measured using an observable market interest rate.
▪ Level 3 – one or more of the significant inputs are not based on observable market data, such as third-party pricing information without adjustments, for the asset or liability. This includes equity investments in unlisted companies measured using the net asset value as a proxy for the fair value of the investment (Net-Asset-Value-Method).
22
| INTERIM STATEMENT 6M 2026 |
The valuation processes, valuation techniques, and types of inputs used for the fair value measurement of the financial instruments previously disclosed in the consolidated financial statements as of December 31, 2025 have remained unchanged.
During the first half of 2026, the Group recognized additional financial instruments measured at fair value. The valuation techniques and significant inputs used for these instruments are described above.
Apart from borrowings, the Group considers the carrying value of the financial instruments to approximate their fair value.
The carrying amounts and fair values of the financial assets and liabilities measured at fair value and at amortized cost as of June 30, 2026 and as of December 31, 2025 are shown in the tables below.
| 06/30/2026 | ||||||||||||||||||||
| in k€ | Carrying amount | Fair value | Level 1 | Level 2 | Level 3 | |||||||||||||||
| Financial assets | ||||||||||||||||||||
| Equity instruments | 26,659 | 26,659 | — | — | 26,659 | |||||||||||||||
| Other financial assets | — | — | — | — | — | |||||||||||||||
| Derivative financial instruments | 1,375 | 1,375 | — | 162 | 1,213 | |||||||||||||||
| Financial assets carried at FVTPL | 28,034 | 28,034 | — | 162 | 27,872 | |||||||||||||||
| Equity instruments | 7,034 | 7,034 | 7,034 | — | — | |||||||||||||||
| Current investments | 117,231 | 117,231 | 117,231 | — | — | |||||||||||||||
| Cash equivalents | 149,690 | 149,690 | 149,690 | — | — | |||||||||||||||
| Financial assets carried at FVTOCI | 273,955 | 273,955 | 273,955 | — | — | |||||||||||||||
| Financial assets carried at fair value | 301,989 | 301,989 | 273,955 | 162 | 27,872 | |||||||||||||||
| Cash and cash equivalents1 | 198,666 | 198,666 | — | — | — | |||||||||||||||
| Receivables and contract assets | 129,639 | 129,639 | — | — | — | |||||||||||||||
| Other financial assets | 22,017 | 22,017 | — | — | — | |||||||||||||||
| Carried at (amortized) costs | 350,322 | 350,322 | — | — | — | |||||||||||||||
| Total financial assets | 652,311 | 652,311 | 273,955 | 162 | 27,872 | |||||||||||||||
| Financial liabilities | ||||||||||||||||||||
| Derivative financial instruments | 2,535 | 2,535 | — | 2,535 | — | |||||||||||||||
| Financial Liabilities carried at FVTPL | 2,535 | 2,535 | — | 2,535 | — | |||||||||||||||
| Financial liabilities carried at fair value | 2,535 | 2,535 | — | 2,535 | — | |||||||||||||||
| Trade and other payables | 49,128 | 49,128 | — | — | — | |||||||||||||||
| Loans and borrowings | 314,494 | 291,932 | — | 291,932 | — | |||||||||||||||
| Other financial liabilities | 737 | 737 | — | — | — | |||||||||||||||
| Carried at (amortized) costs | 364,359 | 341,797 | — | 291,932 | — | |||||||||||||||
| Lease liabilities² | 158,099 | — | — | — | — | |||||||||||||||
| Total financial liabilities | 524,993 | 344,332 | — | 294,467 | — | |||||||||||||||
1 excludes Money Market Funds classified under Cash and cash equivalents amounting to € 149,690k.
2 measurements within the scope of IFRS 16 are exempted from the requirements of IFRS 13 (IFRS 13.6(b)).
23
| INTERIM STATEMENT 6M 2026 |
| 12/31/2025 | ||||||||||||||||||||
| in k€ | Carrying amount | Fair value | Level 1 | Level 2 | Level 3 | |||||||||||||||
| Financial assets | ||||||||||||||||||||
| Equity instruments1 | 45,205 | 45,205 | — | 21,240 | 23,965 | |||||||||||||||
| Derivative financial instruments | 996 | 996 | — | 996 | — | |||||||||||||||
| Financial assets carried at FVTPL | 46,201 | 46,201 | — | 22,236 | 23,965 | |||||||||||||||
| Equity instruments | 1,265 | 1,265 | 1,265 | — | — | |||||||||||||||
| Current Investments | 57,873 | 57,873 | 57,873 | — | — | |||||||||||||||
| Cash equivalents | 159,056 | 159,056 | 159,056 | — | — | |||||||||||||||
| Financial assets carried at FVTOCI | 218,194 | 218,194 | 218,194 | — | — | |||||||||||||||
| Financial assets carried at fair value | 264,395 | 264,395 | 218,194 | 22,236 | 23,965 | |||||||||||||||
| Cash and cash equivalents² | 259,461 | 259,461 | — | — | — | |||||||||||||||
| Receivables and contract assets | 164,258 | 164,258 | — | — | — | |||||||||||||||
| Other financial assets | 24,585 | 24,585 | — | — | — | |||||||||||||||
| Carried at (amortized) costs | 448,304 | 448,304 | — | — | — | |||||||||||||||
| Total financial assets | 712,699 | 712,699 | 218,194 | 22,236 | 23,965 | |||||||||||||||
| Financial liabilities | ||||||||||||||||||||
| Derivative financial instruments | 222 | 222 | — | 222 | — | |||||||||||||||
| Financial Liabilities carried at FVTPL | 222 | 222 | — | 222 | — | |||||||||||||||
| Financial liabilities carried at fair value | 222 | 222 | — | 222 | — | |||||||||||||||
| Trade and other payables | 64,764 | 64,764 | — | — | — | |||||||||||||||
| Loans and borrowings | 276,403 | 249,568 | — | 249,568 | — | |||||||||||||||
| Other financial liabilities | 2,532 | 2,532 | — | — | — | |||||||||||||||
| Carried at (amortized) costs | 343,699 | 316,864 | — | 249,568 | — | |||||||||||||||
| Lease liabilities³ | 171,286 | — | — | — | — | |||||||||||||||
| Total financial liabilities | 515,207 | 317,086 | — | 249,790 | — | |||||||||||||||
1 includes assets held for sale totaling € 3,830k.
2 excludes Money Market Funds classified under Cash and Cash Equivalents amounting to € 159,056k.
3 measurements within the scope of IFRS 16 are exempted from the requirements of IFRS 13 ( IFRS 13.6(b)).
24
| INTERIM STATEMENT 6M 2026 |
The following tables show the development of the fair values of Level 3 for the six months ended June 30, 2026 and during year 2025:
| in k€ | Equity instruments and other financial assets | |||
| Balance as of January 1, 2026 | 23,965 | |||
| Additions and reclassifications | 3,845 | |||
| Disposals | — | |||
| Transfer from Level 2 to Level 3 | 3,830 | |||
| Transfer from Level 3 to Level 2 | — | |||
| Fair value change through P&L | (3,767 | ) | ||
| Balance as of June 30, 2026 | 27,872 | |||
| in k€ | Equity instruments and other financial assets | |||
| Balance as of January 1, 2025 | 21,909 | |||
| Additions and reclassifications | 7,259 | |||
| Disposal | (848 | ) | ||
| Transfer from Level 2 to Level 3 | — | |||
| Transfer from Level 3 to Level 2 | (329 | ) | ||
| Fair value change through P&L | (2,974 | ) | ||
| Dividends received | (1,053 | ) | ||
| Balance as of December 31, 2025 | 23,965 | |||
Additions to Level 3 investments refer to capital increases in Evotec minority investments. As of June 30, 2026, minority investments for a total of € 3,830k have been transferred from Level 2 to Level 3 of the fair value hierarchy as the observable market inputs previously used in the valuation process were no longer considered applicable.
14. Share based Payments
In March 2026, 2,179,470 Share Performance Awards were granted. Thereof, 620,553 were granted to members of the Management Board and the remaining 1,558,917 to other key employees. The exercise price of the options was € 1.00 for both Management Board members and other key employees. The "Fair Market Value” (FMV), which represents the present value of the respective option rights at the Grant Date, is calculated as of January 1 of the respective year. The fair value of the Share Performance Awards on January 1, 2026 was € 5.62 and the share price on the Grant Date, March 20, 2026, was € 4.30.
The fair value of options granted during the six months ended June 30, 2026 was estimated on the Grant Date using the following assumptions:
| Expected dividend yield | — | % | ||
| Expected volatility of Evotec share | 59.00 | % | ||
| Risk-free interest rate | 2.65 | % | ||
| Expected life of share options (years) | 4 |
In addition, a total of 1,628,100 Restricted Share Units were granted in the six months ended June 30, 2026. These Restricted Share Units were granted exclusively to key employees. The fair value of the Restricted Share Units on January 1, 2026 was $ 4.01 and the share price on the Grant Date, March 20, 2026, was $ 3.07.
For the six months ended June 30, 2026, the Group recognized € 2,582k of share-based compensation expense in the income statement (6M 2025: € 3,246k).
During the first half of 2026, employees and members of the Management Board exercised 98,875 Share Performance Awards, 31,777 Restricted Share Awards as well as 133,290 Restricted Share Units, which were settled using treasury shares.
25
| INTERIM STATEMENT 6M 2026 |
15. Related Party Transactions
Evotec’s related parties include associated companies as well as the members of the Supervisory Board and the key management personnel of the Group. Except for the transactions described in Evotec’s Annual Report 2025 Note 20, no other material transactions with related parties were entered into in the first six months of 2026.
16. Subsequent Events
On July 13, 2026, Evotec issued an updated guidance on revenue and adjusted EBITDA for FY2026. The Group expects revenue to be approximately € 570 m to € 610 m (€ 595 m to € 635 m CER) and adjusted Group EBITDA approximately € (70) m to € (105) m (€ (60) m to € (90) m CER), compared with previous guidance of € 700 m to € 780 m (€ 730 m to € 810 m CER) for Group revenues and € 0 to € 40 m (€ 10 m to € 50 m CER) for adjusted Group EBITDA.
26
| INTERIM STATEMENT 6M 2026 |
III. RESPONSIBILITY STATEMENT
To the best of our knowledge and in accordance with the applicable reporting principles for interim financial reporting, the Interim Condensed Consolidated Financial Statements give a true and fair view of the assets, liabilities, financial position and financial results of the Group, and the Group Interim Management Report includes a fair review of the development and performance of the business and the position of the Group, together with a description of the principal opportunities and risks associated with the expected development of the Group.
August 13, 2026
| Dr Christian Wojczewski | Claire Hinshelwood | Aurélie Dalbiez | ||
| Chief Executive Officer | Chief Financial Officer | Chief People Officer |
| Dr Cord Dohrmann | Dr Ingrid Müller | |
| Chief Scientific Officer | Chief Operating Officer |
27
| INTERIM STATEMENT 6M 2026 |
Financial calendar 2026
| November 5, 2026 | Quarterly Statement 9M 2026 |
FORWARD-LOOKING STATEMENTS
This half-year interim report contains forward-looking statements concerning future events. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Adjusted Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to be correct. These statements involve known and unknown risks and are based upon certain assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.
28
Exhibit 99.2
Evotec Announces Second Quarter and First Half 2026 Results: Growing Commercial Momentum
| · | H1 2026 financial performance: Q2 and H1 Group revenues of €143.5 m and €300.1 m, respectively (Q2: €146.3 m, H1: €313.2 m at CER); adj. Group EBITDA of -€20.8 m and -€42.7 m, respectively (Q2: -€18.6 m, H1: -€37.4 m at CER) |
| · | Updated FY 2026 outlook: Expected Group revenues of €570 to €610 m (€595 to 635 m CER) and adj. Group EBITDA of -€70 to -€105 m (-€60 to -€90 m CER), compared with previous guidance of €700 to €780 m (€730 to €810 m CER) for Group revenues and €0 to €40 m (€10 to €50 m CER) for adj. Group EBITDA |
| · | Commercial momentum across segments: Net sales* in D&PD ex-strategic partnerships increased by approximately 28% year-on-year in H1 2026, reflecting improved customer engagement and commercial execution; Just – Evotec Biologics continued to benefit from high capacity utilization and expansion of its customer base |
| · | Horizon execution on track: Transformation progressing as planned across operational excellence, scientific leadership and commercial execution; early cost savings delivered in H1 support confidence in achieving 2026 savings contribution; 2026 contribution of approximately 20-30% of previously announced €75 million annual run-rate savings target by the end of 2027 |
| · | Governance Update: Camilla Macapili Languille stepped down from Evotec’s Supervisory Board |
| · | Additional information available: As final Q2/H1 2026 results are consistent with preliminary results and updated FY 2026 outlook communicated on July 14, 2026, Evotec will not host a separate webcast in conjunction with its final results reporting. The replay, presentation slides and transcript from the July 14 webcast remain available under this link. |
Hamburg, Germany, August 13, 2026 - Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced financial results for the second quarter and first half of 2026 and confirmed its updated full-year 2026 outlook.
*Net Sales: including signed work orders, positive change orders and negative change orders
Page 1 of 6
Dr. Christian Wojczewski, Chief Executive Officer of Evotec, said:
“While the first half of 2026 results reflect the challenging start to the year previously anticipated, we are seeing clear and encouraging signs that our actions are gaining traction. Commercial activity is improving across both segments, with strong growth in D&PD base net sales, increasing customer engagement and continued momentum at Just – Evotec Biologics. At the same time, Horizon is progressing according to plan, supporting greater focus, accountability and efficiency across the organization. While the financial benefits of these developments will take time to fully materialize, they represent important building blocks for recovery and the next phase of growth. We continue to see attractive opportunities across both segments and remain confident in the strength of our strategic partnership pipeline, with a significant portion of opportunities progressing through advanced discussions. Our continued investment in next-generation discovery capabilities, including our proteomics and transcriptomics platforms, strengthens our scientific differentiation, enhances the quality of our partner offerings and expands future opportunities for strategic collaborations.”
Selected Business Highlights
Strategic Partnership Pipeline
Evotec maintains an active strategic partnership opportunity pipeline, supported by ongoing discussions across a broad range of therapeutic areas and modalities. The Company is actively advancing opportunities at various stages of evaluation, including a significant number in advanced due diligence and term sheet discussions. While Evotec remains confident in its ability to enter new strategic partnerships in 2026, the timing, complexity and revenue ramp-up associated with individual agreements remain inherently variable and are reflected in the Company's updated full-year 2026 outlook.
As communicated in the outlook update on July 14, 2026, Evotec expects lower contributions from both existing and potential new strategic partnerships in 2026 than previously anticipated. Approximately 40% of the reduction in expected full-year 2026 revenue relative to the previous outlook reflects revised project phasing and milestone schedules for existing partnerships, with the associated revenues now expected to be recognized in 2027. Approximately 45% reflects lower-than-anticipated contributions from potential new strategic partnerships due to the timing of agreement execution and development activities. Approximately 15% is attributable to lower-than-expected revenue conversion against the Company’s internal ambition for accelerated sales-to-revenue conversion, with the associated revenues now also expected to shift into 2027.
Commercial Execution
Commercial execution remains a key focus area of the Horizon transformation and an important driver of Evotec's path to recovery. Within the Horizon transformation, the Company has strengthened its commercial organization, sharpened customer focus and enhanced business development processes across both segments. These efforts are increasingly reflected in commercial indicators, including higher customer engagement, growing new business activity and improved sales effectiveness.
Page 2 of 6
Commercial momentum across Evotec’s base CRO and CDMO businesses strengthened during the first half of 2026. In Drug Discovery & Preclinical Development (D&PD), net sales increased by more than 28% year-on-year, reflecting improved customer engagement and commercial execution. Just – Evotec Biologics continues to demonstrate positive operating momentum as well, supported by high-capacity utilization and expansion of its customer base.
Based on the typical conversion cycle between sales generation and revenue recognition, increased commercial activity in D&PD is expected to contribute increasingly to revenues from the fourth quarter of 2026 onwards.
Governance Update: Supervisory Board Transition
Camilla Macapili Languille has decided to step down from Evotec's Supervisory Board effective August 7, 2026. Since her appointment in June 2022, she has served as an independent Supervisory Board member and as a member of the Audit & Compliance Committee. Following her departure, Supervisory Board member Wes Wheeler has been appointed by the Supervisory Board to the Audit & Compliance Committee. Evotec would like to thank Ms. Macapili Languille for her commitment and service.
The Supervisory Board has initiated the process to identify a successor and will focus on candidates with strong financial expertise to maintain the Supervisory Board's balanced competency profile and committee composition.
Strategic Evaluation
The strategic evaluation announced in connection with the Company's first quarter 2026 results on May 6, 2026, remains ongoing and continues alongside the implementation of the Horizon transformation program. Additional details regarding the review are available in the Company's Q1 2026 results announcement.
Horizon Transformation
Horizon remains Evotec's framework for the next phase of its transformation, focused on operational excellence, scientific leadership and commercial execution.
Since the launch of Horizon in March 2026, Evotec has continued to advance measures to streamline operations, increase agility and focus resources on areas with the clearest path to value. The updated full-year 2026 outlook does not change the strategic direction of Horizon or the timeline for its implementation.
Evotec remains on track to deliver approximately 20-30% of cost savings in 2026 as part of its previously announced objective of €75 million in annual run-rate savings by the end of 2027. Horizon measures implemented to date are delivering as planned, with first-half savings providing a foundation for achieving the expected 2026 savings contribution.
Page 3 of 6
Financial Results
Claire Hinshelwood, Chief Financial Officer of Evotec, said:
“As previously announced, we confirm that our updated full-year outlook primarily reflects a revised view surrounding strategic partnership activities and milestone contributions in the second half of the year. The reduced contribution from these activities is expected to affect profitability disproportionately relative to revenues, reflecting their typically attractive economics and impact on overall capacity utilization. The current year continues to require disciplined execution and careful cash flow management. We remain focused on driving efficiency across the organization, increasing transparency around our business performance and strategic priorities and delivering on our Horizon objectives. Alongside ongoing cost and footprint optimization, we continue to invest in key strategic areas to support future growth opportunities while preserving financial flexibility.”
Group Financials
For the second quarter of 2026, Group revenues amounted to €143.5 million (€146.3 million CER) compared to €171.2 million in the same period in 2025, representing a 16.2% decrease. Adjusted Group EBITDA was -€20.8 million (-€18.6 million CER), reflecting a decrease of 320.3% versus -€5.0 million in the same prior-year period, mainly driven by lower revenues.
For the six months ended June 30, 2026, Evotec generated Group revenues of €300.1 million (€313.2 million CER), a 19.2% decline versus €371.2 million in the first half of 2025. R&D expenses were managed in line with the Company’s focus on cost discipline, decreasing to €20.3 million (6.8% of total Group revenues) compared to €29.4 million in the prior year (7.9% of total Group revenues). Adjusted Group EBITDA decreased to -€42.7 million (-€37.4 million CER), down from -€1.9 million for H1 2025. The decrease was partially offset by lower cost of revenue as well as reduced R&D and SG&A expenses.
Evotec closed the second quarter of 2026 with a liquidity position of €465.6 million, reflecting a net cash position.
Segment Financials
Discovery and Preclinical Development (D&PD)
For the second quarter of 2026, revenues for Discovery & Preclinical Development amounted to €108.1 million (€109.5 million CER), representing a year-on-year decrease of 15.8%. Adjusted EBITDA for the quarter amounted to -€14.6 million (-€13.0 million CER), down from -€2.5 million in the second quarter of 2025.
For the first half of 2026, revenues totaled €228.1 million (€235.9 million CER), representing a year-on-year decrease of 15.3% compared with €269.0 million in the prior-year period, primarily driven by weak sales to revenue conversion across all business areas and softer-than-expected customer demand, reflecting the continued challenging market environment. Adjusted EBITDA for the segment was -€24.4 million (-€18.4 million CER), compared with -€9.3 million in the prior year, reflecting the reduced topline performance.
Page 4 of 6
Just – Evotec Biologics (JEB)
For the second quarter of 2026, revenues for Just – Evotec Biologics amounted to €35.4 million (€36.8 million CER), representing a year-on-year decrease of 17.4%. Adjusted EBITDA reached -€6.2 million (-€5.6 million CER), down from -€2.5 million in the prior-year period.
For the first half of 2026, revenues totaled €72.3 million (€77.3 million CER), representing a year-on-year decrease of 29.3% from €102.2 million in the same period in 2025. The decline was mainly driven by the non-repeat of the Sandoz license sale in Q1 2025. Adjusted EBITDA amounted to -€18.2 million (-€19.0 million CER), down from €7.5 million in the same period in 2025 based on the Sandoz license sale in Q1 2025.
Re-affirming Full-year 2026 Guidance
As announced on July 14, 2026, Evotec confirms its full-year 2026 outlook for Group revenues of approximately €570 to €610 million (€595 to €635 million CER) and adjusted Group EBITDA of approximately -€70 to -€105 million (-€60 to -€90 million CER). In light of the updated 2026 outlook, Evotec is in the process of reviewing its mid-term framework.
Additional Information
Evotec hosted a webcast and conference call on Tuesday, July 14, 2026. An on-demand replay of the webcast as well as the presentation slides and transcript are available under this link.
About Evotec SE
Evotec is a life science company pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, Evotec accelerates the journey from concept to cure with greater speed, intelligence and precision. The company's expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms including Molecular Patient Databases, PanOmics and induced pluripotent stem cell-based disease modelling. Through flexible partnering models tailored to customers' needs, Evotec works with all Top 20 pharmaceutical companies, more than 800 biotechnology companies, academic institutions and other healthcare stakeholders. Evotec's offerings range from standalone services to fully integrated research and development programmes and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, the company is redefining biologics development and manufacturing to improve accessibility and affordability. With a portfolio of more than 100 proprietary research and development assets, most of which are co-owned, Evotec focuses on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology and immunology. Evotec's global team of around 4,500 experts operates from sites in Europe and the United States, providing complementary technologies and services through a network of synergistic centres of excellence.
Learn more at www.evotec.com and follow Evotec on LinkedIn and X at @Evotec.
Forward-Looking Statements
This announcement contains forward-looking statements concerning future events, including Evotec's preliminary financial results, updated full-year 2026 outlook, expected commercial conversion, anticipated strategic partnership and milestone contributions, Horizon implementation, expected cost savings, liquidity, financial flexibility and future business performance. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of these words and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on information available to Evotec and on expectations and assumptions considered reasonable by the company at the time the statements were made. No assurance can be given that these expectations will prove correct. Forward-looking statements involve known and unknown risks and are based on assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond Evotec's control. Evotec expressly disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement to reflect changes in expectations, events, conditions or circumstances, except as required by applicable law.
Investor Relations and Media Contact
Dr. Sarah Fakih
EVP, Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.com
Page 5 of 6
Key figures of consolidated income statement & segment information
| Three months ended 30 June 2026 | Three months ended 30 June 2025 | |||||||||||||||||||||||
| (in € thousands) | D&PD | JEB | Evotec Group | D&PD | JEB | Evotec Group | ||||||||||||||||||
| Revenues | 108,068 | 35,410 | 143,479 | 128,379 | 42,855 | 171,235 | ||||||||||||||||||
| Intersegment revenues | 109 | - | - | 27 | 23 | - | ||||||||||||||||||
| Costs of revenues | -105,245 | -39,921 | -145,059 | -108,596 | -45,564 | -154.110 | ||||||||||||||||||
| Gross profit | 2,932 | -4,512 | -1,579 | 19,810 | -2,685 | 17,125 | ||||||||||||||||||
| Gross margin in % | 2.7 | -12,7 | -1.1 | 15.4 | -6.3 | 10.0 | ||||||||||||||||||
| R&D expenses | -10,256 | - | -10,257 | -14,469 | -10 | -14,479 | ||||||||||||||||||
| SG&A expenses | -31,669 | -7,621 | -39,290 | -36,600 | -7,275 | 43,874 | ||||||||||||||||||
| Other operating income | 9,037 | 536 | 9,572 | 15,573 | 1,091 | 16,665 | ||||||||||||||||||
| Other operating expense | -46,841 | -928 | -47,768 | -4,162 | 125 | -4,037 | ||||||||||||||||||
| Reorganization costs | -23,950 | -23.050 | 826 | - | 826 | |||||||||||||||||||
| Operating income (loss) | -100,749 | -12,525 | -113,274 | -19,021 | -8,752 | -27,774 | ||||||||||||||||||
| Adjusted EBITDA | -14,638 | -6,194 | -20,833 | -2,472 | -2,485 | -4,957 | ||||||||||||||||||
| Six months ended 30 June 2026 | Six months ended 30 June 2025 | |||||||||||||||||||||||
| (in € thousands) | D&PD | JEB | Evotec Group | D&PD | JEB | Evotec Group | ||||||||||||||||||
| Revenues | 227,868 | 72,254 | 300,123 | 268,969 | 102,244 | 371,213 | ||||||||||||||||||
| Intersegment revenues | 206 | - | - | 29 | 23 | - | ||||||||||||||||||
| Costs of revenues | -217,966 | -85,510 | -303,271 | -227,967 | -92,937 | -320,852 | ||||||||||||||||||
| Gross profit | 10,108 | -13,256 | -3,148 | 41,031 | 9,330 | 50,361 | ||||||||||||||||||
| Gross margin in % | 4.4 | -18.3 | -1.0 | 15.3 | 9.1 | 13.613.6 | ||||||||||||||||||
| R&D expenses | -20,337 | - | -20,338 | -29,346 | -62 | -29,408 | ||||||||||||||||||
| SG&A expenses | -66,496 | -16,582 | -83,078 | -77,779 | -15,631 | -93,410 | ||||||||||||||||||
| Other operating income | 20,967 | 1,063 | 22,029 | 27,885 | 1,756 | 29,642 | ||||||||||||||||||
| Other operating expense | -49,664 | -1,546 | -51,210 | -5,066 | -535 | -5,601 | ||||||||||||||||||
| Reorganization costs | -98,924 | - | -98,924 | 634 | - | 634 | ||||||||||||||||||
| Operating income (loss) | -204,348 | -30,322 | -234,669 | -42,641 | -5,141 | -47,782 | ||||||||||||||||||
| Adjusted EBITDA | -24,438 | -18,245 | -42,684 | -9,329 | 7,478 | -1,850 | ||||||||||||||||||
Page 6 of 6